The Manufacturers Life Insurance Company Sells 95,568 Shares of Gilead Sciences, Inc. $GILD

The Manufacturers Life Insurance Company decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,623,932 shares of the biopharmaceutical company’s stock after selling 95,568 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.21% of Gilead Sciences worth $290,915,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sand Hill Global Advisors LLC bought a new position in shares of Gilead Sciences in the 2nd quarter valued at about $303,000. Sei Investments Co. raised its holdings in Gilead Sciences by 20.2% during the second quarter. Sei Investments Co. now owns 941,608 shares of the biopharmaceutical company’s stock worth $104,393,000 after acquiring an additional 158,199 shares in the last quarter. Dearborn Partners LLC boosted its position in Gilead Sciences by 1.4% during the second quarter. Dearborn Partners LLC now owns 77,560 shares of the biopharmaceutical company’s stock valued at $8,599,000 after purchasing an additional 1,065 shares during the last quarter. NewEdge Advisors LLC boosted its position in Gilead Sciences by 12.6% during the second quarter. NewEdge Advisors LLC now owns 106,489 shares of the biopharmaceutical company’s stock valued at $11,806,000 after purchasing an additional 11,903 shares during the last quarter. Finally, Diadema Partners LP bought a new position in Gilead Sciences in the second quarter valued at approximately $3,326,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.23, for a total transaction of $313,075.00. Following the transaction, the chief financial officer owned 154,555 shares in the company, valued at $19,354,922.65. This trade represents a 1.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. The trade was a 20.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 135,757 shares of company stock worth $16,616,127 in the last 90 days. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on GILD shares. Royal Bank Of Canada upped their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research note on Friday, October 31st. BMO Capital Markets set a $135.00 price target on shares of Gilead Sciences in a research note on Tuesday, November 25th. Argus lifted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research note on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $130.96.

Gilead Sciences Price Performance

Shares of GILD opened at $121.34 on Thursday. The company’s 50-day moving average is $121.48 and its 200-day moving average is $115.57. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a market capitalization of $150.54 billion, a PE ratio of 18.81, a PEG ratio of 0.66 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.